country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-150582

Copy Link Print Information

c-Met-IN-14

c-Met-IN-14 (compound 26af) is a selective inhibitor of c-Met kinase from N-sulfonylamidine-based derivatives, with an IC₅₀ value of 2.89 nM. c-Met-IN-14 shows anticancer activity by blocking phosphorylation of c-Met, and arrests cell cycle at G2/M phase. c-Met-IN-14 induces apoptosis of A549 cells in a dose-dependent manner.

For research use only. We do not sell to patients.

CAS No.: 2443380-34-3
Formula: C₃₄H₃₈ClFN₄O₇S
Molecular Weight:701.20

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (283 KB)

c-Met-IN-14 Chemical Structure

CAS No.: 2443380-34-3

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

IC50: 2.89 nM (c-Met); 4.26 nM (c-kit); 7.28 nM (Flt-3)^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	0.28 μM Compound: 26af	Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 32505087]
FHC	IC₅₀	6.12 μM Compound: 26af	Cytotoxicity against human FHC cells assessed as inhibtion of cell proliferation measured after 72 hrs by MTT assay Cytotoxicity against human FHC cells assessed as inhibtion of cell proliferation measured after 72 hrs by MTT assay	[PMID: 32505087]
HT-29	IC₅₀	0.32 μM Compound: 26af	Cytotoxicity against human HT-29 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 32505087]
HUVEC	IC₅₀	1.35 μM Compound: 26af	Cytotoxicity against human HUVEC cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Cytotoxicity against human HUVEC cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 32505087]
MDA-MB-231	IC₅₀	0.72 μM Compound: 26af	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 32505087]
MKN-45	IC₅₀	0.48 μM Compound: 26af	Cytotoxicity against human MKN-45 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay Cytotoxicity against human MKN-45 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay	[PMID: 32505087]

In Vitro

c-Met-IN-14 (compound 26af) is a relatively selective inhibitor of c-Met kinase (IC₅₀=2.89 nM), because of high inhibitory effects against c-Kit (IC₅₀=4.26 nM) and Flt-3 (IC₅₀=7.28 nM)^[1].
c-Met-IN-14 (0.28-0.72 μM; 24 h) exhibits the remarkable anti-proliferative activities against cancer cell lines (A549, HT-29, MKN-45 and MDA-MB-231), with IC₅₀s of 0.28-0.72 μM^[1].
c-Met-IN-14 (0.25, 0.5, and 1.0 μM; 12 h) induces the late apoptotic and early apoptotic and (0.25, 0.5, and 1.0 μM; 24 h) shows anti-proliferative of A549 cells by arresting cell cycle at G2/M phase and apoptosis induction^[1].
c-Met-IN-14 (1.35, or 6.12 μM, respectively; 24 h) has moderate selectivity towards cancer cells over normal cells, with the selectivity index of 4.2 and 19.1 to HUVEC (IC₅₀=1.35 μM) and FHC cells (IC₅₀=6.12 μM), respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

A549
Concentration:

0, 2, 4, 8 μM
Incubation Time:

6 hours
Result:

Showed excellent inhibition against c-Met phosphorylation in a concentration-dependent manner.

In Vivo

c-Met-IN-14 (compound 26af) (p.o.; 8 mg/kg) exhibits safety profile and favorable pharmacokinetic properties in BALB/c mouse, with rapid absorption (T_max=2.5 h), high maximum concentration (C_max=1228.4 ng/mL), high plasma exposure (AUC_0-∞=6.8 µg.h.mL^-1), accepted elimination half-life (T_1/2=3.5 h), and well clearance (1.18 L.h_-1.kg_-1), has a moderate oral bioavailability (74%) in mouse^[1].
c-Met-IN-14 (i.p.; below 200 mg/kg) doesn’t cause abnormalities, anaphylactic responses, allergic reactions on mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

8-week-old male BALB/c mice ^[1]
Dosage:

0 (vehicle), 100, 200, 300, or 400 mg/kg
Administration:

Intraperitoneal injection; treatment on day 0 and assessment every 3 days for 15 days
Result:

Showed no obvious toxicity in acute toxicity tests.

Animal Model:

Pharmacokinetic profiles of compound 26af in BALB/c mouse^[1]
Dosage:
Administration:
Result:

Route Dose (mg/kg) T_1/2 (h) C_max (ng.mL^-1) T_max (h) AUC_0-∞ (μg.h.mL^-1) CL (L.h^-1.kg^-1) CL (%)

i.v. 2 1.8 675.6 - 2.3 -

p.o. 8 3.5 1228.4 2.5 6.8 1.18 74

Chemical Information

CAS No. 2443380-34-3
Molecular Weight 701.20
Formula C₃₄H₃₈ClFN₄O₇S
SMILES

COCC/C(NC1=CC=C(OC2=CC=NC3=CC(OCCCN4CCOCC4)=C(OC)C=C23)C(F)=C1)=N/S(=O)(CC5=CC=C(Cl)C=C5)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (283 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Nan X, et al. Design, synthesis and biological evaluation of novel N-sulfonylamidine-based derivatives as c-Met inhibitors via Cu-catalyzed three-component reaction. Eur J Med Chem. 2020 Aug 15. 200:112470. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote